Abstract
THIS REPORT:
- Provides an overview of gastrointestinal disorders in the U.S.
- Reviews the gastrointestinal system and explains disorders for their risk
factors and mortality rates
- Offers the current market status for gastrointestinal pharmaceuticals and
forecasts through 2014
- Discusses current pharmaceutical treatments, market size and market
participants in both the prescription and over-the-counter arenas
- Covers potential treatments now in research and development
- Describes the industry in detail, its relationship to the healthcare
industry, its participants and future trends
- Profiles major companies.
SCOPE OF REPORT
This report is designed to be a comprehensive business tool to provide an
in-depth look at gastrointestinal disorders. The geographic scope of the
report is global with a particular emphasis on the United States. Market data
is global. The report provides an overview of the gastrointestinal system;
gives a brief explanation of disorders of the gastrointestinal system; cites
risk factors, where applicable; cites incidence and mortality; presents
current pharmaceutical treatments, market size and market participants in both
prescription and OTC arenas; and presents potential treatments in research and
development, potential market size, and market participants. This report
describes the industry in detail, its relationship to the healthcare industry,
its participants, and its trends for the future.
Within the market for gastrointestinal pharmaceuticals, categories are divided
into two general segments:
- Prescription gastrointestinal pharmaceuticals
- Over-the-counter gastrointestinal pharmaceuticals
The market is further broken down into the drugs to treat specific disorders
within the gastrointestinal system including the following:
- Gastrointestinal tract disorders
- Gastrointestinal tract wall disorders
- Gastrointestinal motility disorders
- Gastrointestinal malabsorption disorders
- Gastrointestinal cancers
Each sub segment is addressed in detail, describing disorders and the
diseases, identifying current and potential products on the market, and
competitors involved in the market.
REASONS FOR DOING THE STUDY
This BCC study is presented to heighten the awareness of gastrointestinal
disorders and identify pharmaceutical preparations and important advancements
in the gastrointestinal markets. The study analyzes therapeutics currently on
the market as well as potential products and classes of products that are
likely to have a significant impact on the future of both the prescription
gastrointestinal drug market and the over-the-counter (OTC) gastrointestinal
drug market. Manufacturers of gastrointestinal drug products have stepped up
the pace of research and development as the engine driving growth in all
markets, especially new treatments for Crohn' s disease and irritable bowel
syndrome (IBS). Because of the evolving nature of the many areas of
gastrointestinal disorders, executives involved in the specific areas within
the gastrointestinal drug market must remain ever vigilant of the changing
environment and strive to keep abreast of current and potential opportunities
within the gastrointestinal marketplace.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based on
extensive firsthand interviews with primary executives, product managers, and
clinical specialists in the gastrointestinal pharmaceutical arena. Background
information was obtained from various government agencies, business and
medical journals, trade magazines, and interviews with doctors and nurses
involved in the treatment of gastrointestinal disorders.
Key information from published literature was used to conduct interviews with
more than 45 industry participants to validate and obtain expert opinions on
current and future trends in the gastrointestinal pharmaceuticals industry.
Interviews were the primary basis for development of market size. Interviews
were also used to confirm and/or adjust market size and market share
estimates, as well as formulating market projections.
All market data pertain to the global market with an emphasis on the U.S.
market at the manufacturer' s level. Data are expressed in current U.S.
dollars. The base year was 2009. Historical data are provided for 2007 and
2008 and forecast data are provided for 2014. Historical, base year and
forecast data are provided for each market segment and sub segment. Market
shares are provided for each market segment for the 2009 base year.
ANALYST CREDENTIALS
Mary Anne Crandall is an expert industry analyst specializing in the
pharmaceutical industry for the last 17 years. She has completed several
in-depth studies on various medical topics requiring both medical expertise
and excellent knowledge of the pharmaceuticals industry. Ms. Crandall has a BS
and MS in psychology and is a retired medical instructor.
| 
View Cart
